



# Proteomics International

LABORATORIES LTD

23 August 2024

The Manager  
Market Announcements Office  
Australian Securities Exchange

Dear Manager,

## **ANNUAL RESULTS**

In accordance with the ASX Listing Rules, attached is the Appendix 4E – Preliminary Final Report.

The Annual Report to shareholders will be released separately.

The Company also advises that the 2024 Annual General Meeting will be held on 1 November 2024. The deadline to receive director nominations is 30 August 2024.

This announcement was authorised to be given to ASX by the Board of Directors of Proteomics International Laboratories Ltd.

Yours faithfully,

Karen Logan  
Company Secretary

For personal use only

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

# Appendix 4E

**Preliminary Final Report**  
**Proteomics International Laboratories Ltd**  
ABN 78 169 979 971

## Dates

<b>Financial Year Ended</b>	30 June 2024
<b>Previous Corresponding Reporting Period</b>	Financial year ended 30 June 2023

## Results for Announcement to the Market

	<b>Current Period (30 Jun 2024) \$</b>	<b>Percentage increase /(decrease) over previous corresponding period</b>	<b>Previous Corresponding Period (30 Jun 2023) \$</b>
<b>Revenue from ordinary activities<sup>1</sup></b>	1,112,184	(16%)	1,323,668
<b>(Loss) from ordinary activities after tax attributable to members<sup>2</sup></b>	(6,376,219)	3%	(6,176,573)
<b>(Loss) for the period attributable to members</b>	(6,376,219)	3%	(6,176,573)

Notes:

- Revenue from continuing operations, research grants and other income have been disclosed as revenue from ordinary activities.
- Net loss for the period from continuing operations has been disclosed as loss from ordinary activities after tax attributable to members

<b>Dividends (distributions)</b>	<b>Amount per security</b>	<b>Franked amount per security</b>
<b>Final Dividend</b>	Nil	Nil
<b>Interim Dividend</b>	Nil	Nil
<b>Record date for determining entitlements to the dividends (if any)</b>	Not Applicable	

For personal use only

## Commentary on the results for the financial year ended 30 June 2024

**Brief explanation of any of the figures reported above necessary to enable the figures to be understood:**

Medical technology company Proteomics International Laboratories Ltd (ASX:PIQ; Proteomics International or the Company) presents this financial report for the year ended 30 June 2024, with the following explanation of the results:

- Combined income from all sources increased 7% to \$3.57 million, encapsulating revenue from analytical services and research grants and the R&D Tax Incentive.
- Operational expenditure increased by 5% to \$10.0 million and focused on the commercialisation of the PromarkerD test and the expansion of the Promarker™ diagnostics pipeline.
- The loss from ordinary activities attributable to members increased 3% to \$6.37 million, which reflects normal operational costs and non-cash items of \$1.51 million (comprising depreciation and the share-based payment expense).
- The net cash outflow from operating activities was \$5.6 million.
- At 30 June 2024, the Company had cash reserves of \$6.6 million, and trade and other receivables of \$0.18 million. On the back of the Company's research and development activities, it anticipates an R&D Tax Incentive cash rebate of \$2.2 million, to be received in the December quarter 2024.

A full description of Proteomics International's operational activities are contained in the Company's Annual Report for 2024 available here:

[www.proteomics.com.au/investors/reports-main-page/2024-reports/](http://www.proteomics.com.au/investors/reports-main-page/2024-reports/)

### **ANNUAL GENERAL MEETING**

In accordance with ASX Listing Rules 3.13.1 and 14.3, Proteomics International advises that its 2024 annual general meeting (AGM) is scheduled to be held on 1 November 2024. The Company encourages shareholders to attend the AGM and receive an update on the strategy and initiatives of the Group.

For personal use only

### Net tangible assets per ordinary share

	30 June 2024	30 June 2023
	\$	\$
Net tangible asset per share	0.07	0.07

### Details of Associates and Joint Venture Entities

	Ownership Interest		Contribution to net profit/(loss)	
	2024 %	2023 %	2024 \$A	2023 \$A
<b>Name of entity</b>	N/A	N/A	N/A	N/A
Associates				
Joint Venture Entities				
Aggregate Share of Losses				

### Details of entities over which control has been gained or lost during the period

Name of entity	N/A
Date of gaining control	N/A
Commentary and contribution	N/A

### Audit Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited	<input checked="" type="checkbox"/>	The accounts have been subject to review	
The accounts are in the process of being audited or subject to review	<input type="checkbox"/>	The accounts have not yet been audited or reviewed	

**If the accounts have not yet been audited and are likely to contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:**

Not applicable.

**If the accounts have been audited contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:**

Not applicable.

For personal use only